全文获取类型
收费全文 | 37344篇 |
免费 | 2638篇 |
国内免费 | 2856篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 544篇 |
妇产科学 | 123篇 |
基础医学 | 2567篇 |
口腔科学 | 34篇 |
临床医学 | 4440篇 |
内科学 | 11398篇 |
皮肤病学 | 160篇 |
神经病学 | 215篇 |
特种医学 | 2671篇 |
外科学 | 8029篇 |
综合类 | 4604篇 |
预防医学 | 1541篇 |
眼科学 | 21篇 |
药学 | 2901篇 |
12篇 | |
中国医学 | 1244篇 |
肿瘤学 | 2310篇 |
出版年
2024年 | 33篇 |
2023年 | 513篇 |
2022年 | 1106篇 |
2021年 | 1380篇 |
2020年 | 1245篇 |
2019年 | 1097篇 |
2018年 | 1123篇 |
2017年 | 965篇 |
2016年 | 1219篇 |
2015年 | 1372篇 |
2014年 | 2612篇 |
2013年 | 2253篇 |
2012年 | 2384篇 |
2011年 | 2465篇 |
2010年 | 2272篇 |
2009年 | 2335篇 |
2008年 | 2376篇 |
2007年 | 2303篇 |
2006年 | 2199篇 |
2005年 | 1791篇 |
2004年 | 1256篇 |
2003年 | 1114篇 |
2002年 | 1008篇 |
2001年 | 882篇 |
2000年 | 751篇 |
1999年 | 610篇 |
1998年 | 538篇 |
1997年 | 488篇 |
1996年 | 409篇 |
1995年 | 391篇 |
1994年 | 378篇 |
1993年 | 271篇 |
1992年 | 242篇 |
1991年 | 183篇 |
1990年 | 152篇 |
1989年 | 149篇 |
1988年 | 135篇 |
1987年 | 90篇 |
1986年 | 80篇 |
1985年 | 90篇 |
1984年 | 66篇 |
1983年 | 39篇 |
1982年 | 62篇 |
1981年 | 63篇 |
1980年 | 47篇 |
1979年 | 41篇 |
1978年 | 52篇 |
1977年 | 37篇 |
1976年 | 35篇 |
1974年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
目的:探讨Ki-67表达与原发性肝癌根治性切除术后行预防性TACE患者预后的关系。方法:采用回顾性队列研究,收集2014年12月—2016年1月福建医科大学孟超肝胆医院150例行原发性肝癌根治性切除术并在术后2个月内行预防性TACE患者的临床病理资料,根据术后肝癌组织病理Ki-67评分分为为低表达组(Ki-67评分≤20%,44例)和高表达组(Ki-67评分20%,106例);分析Ki-67表达量与患者临床病理因素及复发与生存的关系。结果:高表达组肿瘤多发、肿瘤包膜不完整及合并微血管癌栓患者比例明显高于低表达组(均P0.05)。Ki-67高表达与肿瘤多发、肿瘤直径大为影响无瘤生存期的独立危险因素(均P0.05);Ki-67高表达与肿瘤多发、肿瘤直径大、肿瘤包膜不完整、合并微血管癌栓为影响总生存期的独立危险因素(均P0.05);高表达组患者复发率明显高于低表达组(57.9%vs. 37.7%,χ~2=6.777,P0.05),总生存率明显低于低表达组(45.6%vs. 75.9%,χ~2=8.447,P0.05)。结论:Ki-67的表达量对肝癌根治性切除术后行预防性TACE患者的预后有显著影响,高表达者预后不良。 相似文献
52.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献53.
Francesco Esposito Chetana Lim Eylon Lahat Chaya Shwaartz Rony Eshkenazy Chady Salloum Daniel Azoulay 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2019,21(9):1099-1106
BackgroundSome patients remain deemed unsuitable for resection after portal vein embolization (PVE) because of insufficient hypertrophy of the future remnant liver (FRL). Hepatic and portal vein embolization (HPVE) has been shown to induce hypertrophy of the FRL. The aim of this study was to provide a systematic review of the available literature on HPVE as preparation for major hepatectomy.MethodsThe literature search was performed on online databases. Studies including patients who underwent preoperative HPVE were retrieved for evaluation.ResultsSix articles including 68 patients were published between 2003 and 2017. HPVE was performed successfully in all patients with no mortality and morbidity-related procedures. The degree of hypertrophy of the FRL after HPVE ranged from 33% to 63.3%. Surgical resection after preoperative HPVE could be performed in 85.3% of patients, but 14.7% remained unsuitable for resection because of insufficient hypertrophy of the FRL or tumor progression. Posthepatectomy morbidity and mortality rates were 10.3% and 5.1%, respectively. The postoperative liver failure rate was nil.ConclusionHPVE as a preparation for major hepatectomy appears to be feasible and safe and could increase the resectability of patients initially deemed unsuitable for resection because of absent or insufficient hypertrophy of the FRL after PVE alone. 相似文献
54.
Hong Han Hong Ding Zhengbiao Ji Weibin Zhang Qun Wang Wenping Wang 《Ultrasound in medicine & biology》2019,45(2):395-401
The purpose of the study was to evaluate the vascular architecture of focal liver lesions with the newly released non-contrast micro-flow imaging (MFI) technique. Eighty patients with 80 hepatic tumors were enrolled in this study. The richness of displayed blood flow was first compared with color Doppler flow imaging using grades according to Adler's method. The results indicated that MFI outperformed color Doppler flow imaging with a statistically significant difference (p <0.0001). With the enhanced position in arterial phase of contrast-enhanced ultrasound imaging as the ground truth, the displayed blood flow distribution within tumors in MFI was further evaluated. The coincidence rate between MFI and contrast-enhanced ultrasound was 73.75% (59/80), which was higher than that of color Doppler flow imaging (52.5%, 42/80) (p < 0.0001). Moreover, for the five cases of focal nodular hyperplasia, MFI clearly revealed the spoke-wheel or radiating intra-tumoral vasculature, a finding specific to the diagnosis of focal nodular hyperplasia. 相似文献
55.
随着肝介入活检术的快速发展,其在临床诊疗中的应用日益增多。如何选择更好的设备和材料、优化肝介入活检术诊疗流程、减少并发症的发生是目前研究的热点问题。该文从操作设备、手术方式、辅助技术、新型材料等方面回顾了近三年肝介入活检术的研究进展。 相似文献
56.
57.
目的:为进一步深入研究和探讨肝阴虚证候的本质,本文分析和整理肝阴虚证的病因病机、证候表征、证候属性疾病及遣方选药的规律。方法:运用检索文献并进行频数统计的方法,检索查阅1960年9月1日至2019年1月10日中国知网中医临床研究文献。结果:肝阴虚证的病因病机为肝失疏泄,气机郁滞,化火伤阴,阴液亏虚,失于濡养;证候辨证要点主要为脉弦细数,舌红少津,头晕目眩,五心烦热,口咽干燥,两目干涩;证候临床属性疾病有肝炎、肝硬化、肝纤维化、肝癌;临床上治疗肝阴虚证使用处方主要为一贯煎、补肝汤、四物汤、芍药甘草汤,临床高频使用中药为生地黄、白芍、枸杞、当归、麦冬。结论:本文对于肝阴虚证的证候特点以及辨证用药规律做出系统的总结与归纳,将有关肝阴虚证的论述联系起来,形成统一的整体,为揭示肝阴虚证的本质与临床上形成较为成熟的肝阴虚证治疗方案提供参考。 相似文献
58.
59.
目的 比较接受巴塞罗那临床肝癌分期系统(BCLC)或香港的分期系统(HKLC)推荐治疗方案对肝细胞肝癌(HCC)患者生存率的影响。方法 回顾性分析436例初治肝癌患者的临床资料,根据HKLC和BCLC进行肿瘤分期,按是否最终接受两个分期系统推荐的治疗方案分组。比较患者是否接受BCLC或HKLC分期推荐方案治疗对生存率的影响,并评估拒绝BCLC或HKLC推荐方案对预后可能产生的影响。 结果 接受BCLC推荐治疗方案的患者5年生存率显著高于拒绝推荐治疗方案的患者(48% vs. 30%, P<0.001)。与拒绝推荐治疗方案的患者相比,接受HKLC推荐治疗方案的患者亦有较高的5年生存率(41% vs. 29%, P<0.001)。对BCLC和HKLC交叉亚组分析,BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb、BCLC-B/HKLC-Ⅲa+Ⅲb和BCLC-C/HKLC-Ⅲa+Ⅲb亚组中,接受手术切除的HCC患者显著高于接受TACE、索拉非尼或最佳支持治疗的患者5年生存率均较高(均P<0.05)。 结论 接受BCLC和HKLC分期系统推荐治疗方案可以提高HCC患者的存活率,但对于中晚期肝癌患者指导作用减弱。部分BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb、BCLC-B/HKLC-Ⅲa+Ⅲb和BCLC-C/HKLC-Ⅲa+Ⅲb的患者通过积极的根治性治疗可以获得更好的生存。 相似文献
60.